GenVec | GNVC | Profile | Summary

GenVec, (GNVC) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of the company's strategy is to develop and commercialize products through collaborations. GenVec

is working with leading companies and organizations such as Novartis, Merial

, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns.

GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV).

The GenVec's Advantage

1/6

The company's core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector

to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body.

GenVec's novel proprietary adenovectors

No pre existing immune recognition

Built on rare human and nonhuman adenovirus serotypes

New GC technology shows superior performance for genetic vaccines

Multiple capsid modified vectors -AdH technology

Multiple genes/multiple antigens

Targeted a	and specific	delivery	Proprietary	adenovectors	and	cell
lines						

Novel proprietary non replicating adenovirus vectors

Very low sero -prevalence in humans

Outstanding gene/antigen delivery properties

Cell line master banks and master file with FDA

Hearing Restoration Molecular Therapeutic

Dengue Virus Genetic Vaccine

Foot and Mouth Virus Genetic Vaccine

Malaria Genetic Vaccine

RSV Genetic Vaccine

HSV Molecular Therapeutic and Genetic Vaccine

A platform of adenovirus vectors built to meet

product needs for molecular therapeutics and


genetic vaccines

(R)

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, <u>MakeMoney</u>!

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks. OTCKing.com is an OxBridge

affiliate/partner website.



Disclosure/Disclaimer:- OxBridge Research publishes sponsored research reports, advertorials and corporate profiles on its portal and several other websites/blogs, including this website/blog, owned and operated by Ox

Bridge

and/or its affiliates.

OxBridge

Research is not a Broker Dealer or a Registered Financial Adviser in any jurisdiction, whatsoever. All the information published on its website(s) and/or distributed to its members via various electronic means is for general awareness and entertainment purpose only. OxBridge

urges investors to do their own due diligence and consult with their financial adviser prior to making any investment decision. We are expecting a payment from the company/a third party/shareholder. We receive compensation from companies for providing various IR

services, including publication, advertisement, and social media awareness, therefore our views/opinion are inherently biased. Please read the full disclosure/disclaimer, if you need assistance

Friday, 06 September 2013 16:19 - Last Updated Monday, 16 September 2013 02:17

contact

Editor@OxBridgeResearch.com

OxbridgeResearch.com, All Rights Reserved. Trademarks/logos are of their respective owners.

It's YOUR money - Invest WISELY TM